Dabigatran

From Citizendium
Revision as of 06:30, 30 September 2009 by imported>Meg Taylor (subpages)
Jump to navigation Jump to search
This article is a stub and thus not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Dabigatran&printable=yes
This editable Main Article is under development and subject to a disclaimer.

In medicine, dabigatran is an anticoagulant that is a direct thrombin inhibitor[1]

In 2009, dabigatran, a direct thrombin inhibitors, was compared to warfarin in the RE-LY randomized controlled trial.[2]

Dabigatran versus warfarin for atrial fibrillation[2]
Intervention Outcomes
Stroke or systemic embolism Major bleeding Mortality
Dabigatran 110 mg twice daily 1.53% 2.71%† 3.75%
Dabigatran 150 mg twice daily 1.11%† 3.11% 3.64%
Warfarin 1.69% 3.36% 4.13%
† p < 0.05 as compared to warfarin group

References

  1. ↑ Anonymous (2024), Dabigatran (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ 2.0 2.1 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (2009). "Dabigatran versus Warfarin in Patients with Atrial Fibrillation.". N Engl J Med 361 (12): 1139-1151. DOI:10.1056/NEJMoa0905561. PMID 19717844. Research Blogging.
Retrieved from "https://citizendium.org/wiki/index.php?title=Dabigatran&oldid=690141"